Table 2.

Cardiac tissue omega-3 polyunsaturated fatty acid content.

	EPA	DHA	Omega-3 index
RIGHT ATRIUM
Placebo
VF−	0.11 ± 0.08	0.16 ± 0.10	0.27 ± 0.18 (n = 3)
VF+	0.36 ± 0.12	0.58 ± 0.17	0.91 ± 0.25 (n = 6)
n−3 PUFA
VF−	2.04 ± 0.31*	2.89 ± 0.33*	4.92 ± 0.59* (n = 23)
VF+	1.62 ± 0.25*	2.80 ± 0.37*	4.41 ± 0.61* (n = 22)
LEFT VENTRICLE
Placebo
VF−	0.12 ± 0.06	0.19 ± 0.06	0.31 ± 0.11 (n = 3)
VF+	0.34 ± 0.05	0.45 ± 0.10	0.80 ± 0.13 (n = 6)
n−3 PUFA
VF−	2.98 ± 0.30*	3.00 ± 0.17*	5.98 ± 0.43* (n = 23)
VF+	2.27 ± 0.28*	2.80 ± 0.20*	4.41 ± 0.43* (n = 21)

All values are expressed of % of the total lipid content. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; omega-3 index, EPA + DHA, *P < 0.01 placebo vs. n−3 PUFA (omega-3 polyunsaturated fatty acids). There were no significant differences between VF− (resistant to ventricular fibrillation) and VF+ (susceptible to ventricular fibrillation) for either the placebo or n−3 PUFA treated animals.